Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Niels Neymark"'
Publikováno v:
PharmacoEconomics. 23:1155-1166
Background: During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aee3edd8191c5ab4df17b113cda685a
https://doi.org/10.2165/00019053-200523110-00007
https://doi.org/10.2165/00019053-200523110-00007
Autor:
Niels Neymark, Pilar Lianes, Rabab Gaafar, Franz M.N.H. Schramel, Hans Smit, Chris Manegold, Jan P. van Meerbeeck, Egbert F. Smit, C. Debruyne, Bonne Biesma, Catherine Legrand, Giuseppe Giaccone
Publikováno v:
Journal of Clinical Oncology, 21, 3909-3917. American Society of Clinical Oncology
Purpose: To compare the therapeutic efficacy of paclitaxel plus cisplatin (arm A) versus gemcitabine plus cisplatin (arm B) and arm A versus paclitaxel plus gemcitabine (arm C) in chemotherapy-naive patients with advanced non–small-cell lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142e68c6d2f8639b29ee093d6070ed5c
https://doi.org/10.1200/jco.2003.03.195
https://doi.org/10.1200/jco.2003.03.195
Autor:
Niels Neymark, R Crott
Publikováno v:
European Journal of Cancer. 38:147-150
This article describes the activities of the EORTC Health Economics Unit since its inception in early 1994. The aim of the unit is to carry out economic evaluations of competing treatment options in common cancers in order to provide health care deci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be231a5cad76530bb96b1a87e8fb44aa
https://doi.org/10.1016/s0959-8049(01)00465-8
https://doi.org/10.1016/s0959-8049(01)00465-8
Publikováno v:
Health Economics. 11:233-248
The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758cf90c1ef8abad5b95d0529a8eba26
https://doi.org/10.1002/hec.662
https://doi.org/10.1002/hec.662
Publikováno v:
PharmacoEconomics. 20:485-497
Objective: To assess the economic impact of two polychemotherapy regimens for patients with advanced ovarian cancer from the perspective of the Belgian health insurance and financing system. Design: An economic evaluation was integrated in an intergr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11ad23c8acb16e4b0a1f0593ec7dcb88
https://doi.org/10.2165/00019053-200220070-00006
https://doi.org/10.2165/00019053-200220070-00006
Publikováno v:
European Journal of Cancer. 37:1768-1774
We present a retrospective cost-effectiveness analysis using data from a randomised controlled trial (EORTC 22863) of the addition of early hormonal therapy with a luteinising hormone-releasing horn-tone (LHRH) analogue to radiotherapy in the treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea1572e14a1da7210041b59de923a9d1
https://doi.org/10.1016/s0959-8049(01)00197-6
https://doi.org/10.1016/s0959-8049(01)00197-6
Autor:
Niels Neymark
Publikováno v:
Critical Reviews in Oncology/Hematology. 30:1-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d839252f487c3773852e458cc1d540b4
https://doi.org/10.1016/s1040-8428(98)00026-2
https://doi.org/10.1016/s1040-8428(98)00026-2
Autor:
Niels Neymark
With ever increasing demands on the constrained resources available for health care services, no one involved in decision making in health care can continue to ignore the economic costs of the services provided or the relative value for money offered
Autor:
Niels Neymark, Koen Torfs
Publikováno v:
European Urology. 31:72-81
The guiding principles of the predominant methods of economic evaluation, cost-effectiveness analysis and cost-utility analysis, are briefly outlined, stressing the usefulness of the methods as a systematic approach to a structured and consistent ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6856e0f022329e0ac69e251393ed323d
https://doi.org/10.1159/000474534
https://doi.org/10.1159/000474534
Autor:
Niels Neymark
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 1(2)
Anemia is a common occurrence in cancer patients, as a consequence of the disease process and treatment. Until recently, the only treatment available for anemia was red blood cell transfusions, but this was withheld until the development of severe an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991bb31fa10f1283c906ec26eba8b9f4
https://pubmed.ncbi.nlm.nih.gov/19807404
https://pubmed.ncbi.nlm.nih.gov/19807404